Why investors just put $315m behind AdvanCell’s prostate cancer alpha therapy
AdvanCell’s US$315 million Series D backs ADVC001 trials and Lead-212 manufacturing, but Phase 2 evidence remains the decisive test.
Pharma & Biotech
Medical Devices & Diagnostics
Will Biobeat’s wearable BP patch become the new standard in hypertension diagnosis?
Biobeat raises $50M to commercialize its FDA-cleared patch-worn ABPM system. Find out how this device could change hypertension care in the U.S.